Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AC Immune (ACIU) Net Income towards Common Stockholders: 2014-2024

Historic Net Income towards Common Stockholders for AC Immune (ACIU) over the last 11 years, with Dec 2024 value amounting to -$58.1 million.

  • AC Immune's Net Income towards Common Stockholders fell 412.11% to -$19.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$107.6 million, marking a year-over-year decrease of 67.13%. This contributed to the annual value of -$58.1 million for FY2024, which is 4.94% up from last year.
  • Per AC Immune's latest filing, its Net Income towards Common Stockholders stood at -$58.1 million for FY2024, which was up 4.94% from -$61.1 million recorded in FY2023.
  • AC Immune's Net Income towards Common Stockholders' 5-year high stood at -$58.1 million during FY2024, with a 5-year trough of -$79.9 million in FY2021.
  • Over the past 3 years, AC Immune's median Net Income towards Common Stockholders value was -$61.1 million (recorded in 2023), while the average stood at -$64.2 million.
  • As far as peak fluctuations go, AC Immune's Net Income towards Common Stockholders crashed by 249.18% in 2020, and later climbed by 16.75% in 2023.
  • AC Immune's Net Income towards Common Stockholders (Yearly) stood at -$68.5 million in 2020, then decreased by 16.63% to -$79.9 million in 2021, then grew by 8.06% to -$73.4 million in 2022, then climbed by 16.75% to -$61.1 million in 2023, then grew by 4.94% to -$58.1 million in 2024.